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a b s t r a c t
The present study investigated the effects of a new bradykinin B1 receptor antagonist, R-954, on the
development of Ehrlich ascitic tumor (EAT) induced by the intraperitoneal inoculation of EAT cells inmice
and the formation of a solid tumor by the subcutaneous injection of the cells in rat paw. The development
of the tumorwas associatedwith an increase inmouse total cell counts in bonemarrow (10.8-fold), ascitic
ﬂuid (14.6-fold), and blood (12.6-fold). R-954 (2mg/kg, s.c.) signiﬁcantly reduced the ascitic ﬂuid volume
(63.7%) and the mouse weight gain (30.5%) after 10 consecutive days of treatment. The B1 antagonist as
well as the anti-neoplasic drug vincristine also signiﬁcantly inhibited the increase in total cell count in
bone marrow, ascitic ﬂuid, and blood. R-954 reduced signiﬁcantly the total protein extravasation (57.3%),ancer
radykinin
hrlich ascitic tumor
the production of nitric oxide (56%), PGE2 production (82%), and TNF release (85.7%) in mice peritoneal
cavity whereas vincristine reduced the release of these inﬂammatory mediators by 84–94%. The increase
in paw edema after intraplantar injection of EAT cells was reduced by approximately 52% by either R-954
or vincristine treatment. In conclusion, this study presents for the ﬁrst time the antitumoral activity of a
new bradykinin B1 receptor antagonist on ascitic and solid tumors induced by Ehrlich cell inoculation in
mice and rats.. Introduction
Bradykinin is a peptide with several biological activities includ-
ng vasodilation, vascular permeability, and pain (reviewed in
6,23]). Bradykinin was shown to play a role in various pathological
tates, including inﬂammation [46,47,54], shock [4,11], hyperten-
ion [32,35], and airway diseases [43]. Other studies have reported
hat bradykinin stimulated angiogenesis in vivo [21], increased vas-
ular permeability in ascitic tumors and promoted tumor growth
28,33,58]. The ﬁrst evidence for the presence of bradykinin recep-
ors in lung cancer was presented in 1989 by Woll and Rozengurt
56].Many reports further related thepresenceof these receptors in
wide variety of cancers [1,7,48]. Bradykinin and desArg9-BK could
ct as a growth factor for a number of tumor types. Furthermore
everal tumor cells can generate bradykinin and express its recep-
ors which in turn favor an autocrine stimulation of tumor growth.
radykinin could not only stimulate tumor growth directly but
lso stimulate their neovascularization by stimulating the release
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of vascular endothelial growth factor [22], acting as a pluripotent
agent for stimulating tumor growth and invasion [57].
Biological actions of kinins are mediated by two G protein-
coupled receptors, designated Bl and B2 [6,29,30,45]. B2 receptors
are constitutively expressed in a wide variety of tissues whereas Bl
receptors arenotnormallypresent inmost tissues, but their expres-
sion is rapidly induced in various inﬂammatory conditions. It has
been suggested that the B1 receptor might represent an attractive
target in prostate carcinoma [2,52]. Their results showed that there
is a cross-talk between the two receptor subtypes in the prolif-
eration of PC-3 cells. It appears that both BK and desArg9-BK can
induce the activation of ERK and Akt pathways and PC-3 prolif-
eration through the B1 receptors. Surprisingly, inhibition of either
receptors was sufﬁcient to block kinin-induced ERK activation and
cell proliferation. Another study supported more clearly the partic-
ipation of the B1 receptors in prostate cancer. This group found that
the expression of these receptors is restricted to tumorous prostate
tissues whereas the B2 appeared more widely expressed in normal
and diseased prostate [52].
In brief bradykinin antagonists are under investigation as new
Open access under the Elsevier OA license.antitumoral drugs and the B1 receptor appears to be a potential tar-
get for adjunctive therapy of hormone-refractory prostate cancers.
The major advantage of a combination in cancer chemotherapy in
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s the aim of several investigators [50]. In search of more potent
nd more selective bradykinin antagonists as potential anticancer




All experiments were performed with male Balb/C mice
20–25g) or male Wistar rats (150–200g) obtained from our own
nimal facility. Animalsweremaintained in a roomwith controlled
emperature 22±2 ◦C for 12h light/dark cycle, with free access
o food and water. Animals were killed in a chamber with satu-
atedCO2 atmosphere to avoidhemorrhage in theperitoneal cavity.
nimal care, research and animal sacriﬁce protocols were in accor-
ance with the principles and guidelines adopted by the Brazilian
ollege of Animal Experimentation (COBEA), were approved by the
iomedical Science Institute/UFRJ Ethical Committee for Animal
esearch, and received the protocol number ICBDFBC-015.
.2. Treatment regimen
The bradykinin B1 receptor antagonist R-954 (Ac-Orn-[Oic2, a-
e Phe5, D-b Nal7, Ile8] desArg9 bradykinin) [36] was dissolved
n sterile phosphate buffer saline (PBS) and administered subcu-
aneously at the dose of 2mg/kg in a ﬁnal volume of 0.1ml per
nimal. Vincristine sulfate (Sigma Chem., St Louis, MO, USA) was
sed at the optimal concentration of 0.5mg/kg for comparison pur-
ose. The control group was given the vehicle (PBS). Mice and rats
ere given R-954 or vehicle every 24h after inoculation of Ehrlich
scitic tumor cells until the end of experiment.
.3. Ehrlich tumor
Ehrlich ascitic tumor (EAT) cells derived from a spontaneous
urine mammary adenocarcinoma, were maintained in the ascitic
orm by sequential passages in Balb/C mice by means of weekly
.p. transplantations of 5×105 tumor cells. For the experiments on
scitic tumor, mice were given an i.p. inoculation of 5×105 tumor
ells in 0.5ml and were sacriﬁced 10 days after. Samples of blood,
onemarrow lavage and ascitic ﬂuidwere colleted for severalmea-
urements as described. For the series of experiments on rat solid
umor, 5×105 tumor cells were injected in a volume of 0.1ml in
he footpad of rats and the contralateral paw was administered the
ehicle [19]. Every 24h and until the 7th day, the paw edema was
easured by pletismography as described in [16].
.4. Total cell counts
Bone marrow cells were obtained by ﬂushing the femoral cav-
ty with 1ml of PBS. A blood aliquot was collected for cell count.
he ascitic ﬂuid collected was centrifuged at 170× g for 10min at
◦C. The supernatant was recovered for prostaglandin E2, TNF,
rotein and nitric oxide measurements. Aliquots from ascitic cell
uspension, bonemarrowcells, andbloodwerediluted1:20 in Turk
olution (20% acetic acid containing 0.5% Trypan Blue) for total cell
ount in a Newbauer chamber.
.5. Total protein, PGE2, and TNF˛ quantiﬁcationsProtein concentration was determined by the BCA method
BCATM Protein Assay Kit, Pierce, IL, USA). The concentration of
GE2 was determined with an EIA commercial kit (Cayman Chemi-
al Co.,MI,USA) according to themethodof [42]. Brieﬂy, dilutionsofs 32 (2011) 1849–1854
the supernatants were incubated with the conjugated eicosanoid-
acetylcholinesterase and the speciﬁc antiserum in 96-well plates
pre-coated with anti-rabbit immunoglobulin G antibodies. After
an overnight incubation at 4 ◦C, the plates were washed and the
enzyme substrate (Elmman’s reagent)was added and incubated for
60–120min at 25 ◦C. The optical density of the samples was deter-
mined at 412nm in a microplate reader, and the concentration of
PGE2 was calculated from a standard curve. TNF activity in the
ascitic ﬂuid was determined by bioassay using L929 cells based on
the method described by Flick and Gliford [17].
2.6. Quantiﬁcation of nitric oxide (NO) production
To evaluate NO production, the nitrate concentration in the
ascitic ﬂuidwasmeasured through conversionof nitrate intonitrite
[44] followed by the Griess reaction [20]. Brieﬂy, equal volumes
of ascitic ﬂuid and Griess reagent (1% sulphanilamide, 0.1% naph-
thylethylene diamine dihydrochloride, 10% phosphoric acid) were
incubated for 10min at room temperature. The absorbance was
measured at 540nm using a microplate reader, and the nitrite con-
centration was calculated using a standard curve of sodium nitrite.
2.7. Statistical analysis
All experimental groups were composed by 6–8 animals. The
results are presented as the mean± S.D. Statistical signiﬁcance
between groups was determined by an analysis of variance ANOVA
followed by the Bonferroni’s test. Signiﬁcant levels were deﬁned as
the P value being less than 0.05.
3. Results
3.1. Effect of R954 on Ehrlich ascitic tumor (EAT) volume, animal
weight and survival
Intraperitoneal injection of EAT cells resulted in amarked ascitic
liquid accumulation in mice. Maximal volume peaked the 10th day
after the inoculation, after which no signiﬁcant increase in vol-
ume was observed. After this period an intense hemorrhage was
observed in the peritoneal cavity. In view of these initial observa-
tions, all experiments were performed on the 10th day after tumor
inoculation. Mice treatment with the B1 receptor antagonist R-954
(2mg/kg, s.c.) for 10 days caused a signiﬁcant reduction of ascitic
ﬂuid volume collected from the peritoneal cavity. The inhibitory
effect was signiﬁcant after the 9th day of treatment and persisted
until the end of the experiment. Maximal inhibitory effect was
observed the 9th (62.7% reduction) and 10th days (63.7% reduc-
tion) of treatment and declined slightly towards the end of the
experiments (Fig. 1A).
Daily treatment with R-954 inhibited the weight gain of EAT-
inoculated mice as compared to untreated mice and the maximal
inhibitory effectwas obtained the9th and10thdays (31% and30.5%
reduction, respectively, Fig. 1B). When mouse survival was eval-
uated, it was noted that the ﬁrst animal died on the 9th day in
EAT-inoculated group of mice. At the 10th day a 20% death toll was
noted, and only 50% of the animals were alive on the 15th day. In
the R-954-treated group of mice, only one animal died during the
experimental period and this death occurred only after 14 days of
consecutive treatment (Fig. 1C).
3.2. Effect of R-954 on blood, ascitic lavage, and bone marrow cell
numbersOn the 10th day after EAT cell inoculation into mice, a 12.6-
fold increase of total blood cell count was observed (0.5±0.2×107
cells in control group vs. 6.3±2.1×107 cells in EAT-inoculated
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Fig. 1. Effect of R-954 in Ehrlich ascitic tumor-bearing mice. Mice were inoculated
i.p. with 5×105 Ehrlich ascitic tumor cells. Twenty four hours after EAT inoculation
and during the subsequent days, mice were treated with vincristine (0.5mg/kg, i.p.)
or R-954 (2mg/kg, s.c.). In (A) ascitic ﬂuid was collected and volume measurements
were performed as described on methods section; in (B) mice were weighed; in (C)

















Fig. 2. Effect of R-954 on total blood, ascitic, and bone marrow cell counts. Mice
were inoculated i.p. with 5×105 Ehrlich ascitic tumor cells. Every 24h after inocu-
lationmicewere treatedwith vincristine (0.5mg/kg, i.p.) or R-954 (2mg/kg, s.c.). On
the 10th day mice were sacriﬁced. Ascitic ﬂuid was collected and total cell counts
in the ascitic ﬂuid, blood and bone marrow were performed as described in Sec-
tion 2. Statistical signiﬁcance was calculated by ANOVA followed by Bonferroni’s
#
developed at the inoculation site (data not shown). Treatment ofance was calculated by repetitive ANOVA followed by Bonferroni’s test (n=6–8).
P<0.05vincristineorR-954-treatedmicecomparedwith thevehicle-treatedgroup.
ice). This effect was accompanied by a proportional increase
n total bone marrow cell count (0.12±0.02×107 cells in con-
rol group vs. 1.3±0.02×107 cells in EAT-inoculated mice)
nd on cells from ascitic lavage (0.8±0.3×107 cells in control
roup vs. 11.7±1.1×107 cells in EAT-inoculated mice). Vin-
ristine (0.5mg/kg, i.p.) a well known carcinostatic agent used
or comparison purpose reduced total blood cell counts by 55.5%
6.3±2.1×107 cells in EAT-inoculatedmice vs. 2.8±0.8×107 cells
n vincristine-treated EAT inoculated mice), total bone marrow cell
ount by 76.9% (1.3±0.02×107 cells in EAT-inoculated mice vs.
.3±0.2×107 cells in vincristine-treated EAT inoculated mice),
nd total cells in ascitic ﬂuid by 71.8% (11.7±1.1×107 cells in EAT-
noculated mice vs. 3.3±1×107 cells in vincristine-treated EAT
noculated mice). Treatment of animals previously inoculated withtest (n=6–8). P<0.05 when comparing vehicle-treated mice with naïve group and
*P<0.05 when comparing vincristine or R-954-treated mice with vehicle-treated
group.
EAT cells with B1 antagonist R-954 reduced total blood, bone mar-
row, and ascitic cell counts to values similar to vincristine-treated
mice (3.2±0.9; 0.5±0.1; 4.8±1.1×107 cells, respectively) (Fig. 2).
3.3. Effect of R-954 on inﬂammatory mediator production
In order to evaluate inﬂammatory mediator release after EAT
inoculation, mice were sacriﬁced on the 10th day after tumor cell
injection. Peritoneal ascitic ﬂuid was collected and total protein,
nitric oxide, PGE2, and TNF were measured. In mice inocu-
lated with EAT cells, marked increases of the total proteins (from
13.8±3.1 to 493.5±33.8mg/ml), nitric oxide (from 2.8±3.3 to
76.9±12.7M), PGE2 (from 28.4±5.9 to 344.9±45.8pg/ml), and
TNF (from 31.7±9.9 to 792.3±113.4 U/ml) were noted when
compared to the levels in the ﬂuids of non-inoculated animals.
Treatment of mice with R-954 reduced signiﬁcantly the total pro-
tein extravasation (57.3%) as well as the production of nitric oxide
(56%), PGE2 (82%) and TNF (85.7%). The antitumoral drug vin-
cristine also signiﬁcantly reduced by 92% the protein extravasation,
by 84.5% nitric oxide, by 94.7% PGE2, and by 92.2% TNF levels
(Table 1).
3.4. Effect of R-954 on solid Ehrlich tumor in rat paw
When Ehrlich cells are inoculated intraperitoneally, the tumor
processdevelops inanascitic formbutwhen thecells are inoculated
subcutaneously, the tumor develops in a solid form. The solid form
was also used to study antitumoral activity of R-954. In the present
study, the intraplantar injection of 105 EAT cells in rats induced
a tumor and a progressive increase of paw edema which reached
a plateau on the 6th day after inoculation. After this time period,
the paw edema did not increase further and necrotizing tissuesrats with the B1 antagonist R-954 for 6 days signiﬁcantly reduced
(51.4%) the edema formation. When the treatment was prolonged
for more than 6 days, animals did not develop necrotizing tissues
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Table 1
Effect of the B1 receptor antagonist R-954 treatment on protein extravasation, nitric oxide (NO), PGE2 and tumor necrosis factor (TNF) production in peritoneal ascitic ﬂuid.
Treatment mg/kg Total protein (mg/ml) NO (M) PGE2 (pg/ml) TNF (U/ml)
Vehicle – 493.5 ± 33.8 76.9 ± 12.7 344.9 ± 45.8 792.3 ± 113.4









































rR-954 2 210.9 ± 38.7*
tatistical signiﬁcance was calculated with ANOVA followed by the Bonferroni’s tes
* P<0.05 when R-954 or vincristine-treated mice were compared with vehicle-tr
data not shown). Similar results were obtained with vincristine
52.5% reduction) used as positive control (Fig. 3).
. Discussion
This studypresents for theﬁrst time the antitumoral activity of a
ew bradykinin B1 receptor antagonist (R-954) on ascitic and solid
umors induced by Ehrlich cell inoculation in mice and rats. The
esults showed that the inoculation of Ehrlich tumor cells in mice
nduced the formation of large ascitic tumors which were maximal
fter 9–10 days. The size of the tumor did not increase further in the
ollowing days. Although only one animal died on the 9th day after
he inoculation, the death toll increased to 20% the following day
nd to 50% the 15th day. The treatment of Ehrlich tumor-bearing
ice with R-954 during 10 days after tumor inoculation resulted
n a signiﬁcant reduction of ascitic volume which clearly suggested
hat the B1 receptors was involved in the growth of this invasive
umor. At the effective doses used, compound R-954 showed no
igns of general toxicity; the mouse weight gain was normal and
nternal organs did not show abnormalities (data not shown). In
he group of animals which was given R-954 only one animal died
uring the full experimental period (after 15 days of treatment).
his is in sharp contrast to the effects of the standard anti-cancer
rugs vincristine used for comparison. At the doses of vincristine
sed to obtain the reported tumor inhibition, the mice were sick
nd did not gain weight.
Ehrlich tumor has been used as a transplantable tumor model
o investigate the antineoplastic effects of several pharmacological
gents. Following the intraperitoneal inoculation of Ehrlich tumor
ells, the ascitic volume and number of tumor cells were shown to
ncrease progressively [55]. Ascitis in the peritoneal cavity is the
esult of tumor-induced inﬂammation as shown by peritoneal vas-
ular permeability increase and release of several inﬂammatory
ediators [14,15]. The exact mechanisms of the inhibitory effect
f R-954 are still unknown but unpublished results showed that
his compound did not have cytotoxic activities against up to 40
ypes of cancer cells. Its selective inhibitory action on tumor growth
ig. 3. Effect ofR-954on ratpawsolidEhrlich tumor. Ratsweregivenan intraplantar
njection of 5×105 Ehrlich ascitic tumor cells. Every 24h after inoculation rats were
reated with vincristine (0.5mg/kg, i.p.) or R-954 (2mg/kg, s.c.) and paw edema was
easured. Statistical signiﬁcance was calculated by repetitive ANOVA followed by
onferroni’s test (n=6–8). *P<0.05 when comparing vincristine or R-954-treated
ats with vehicle-treated group.33.8 ± 9.9* 61.9 ± 10.9* 113.4 ± 39.7*
–8).
group.
was suggested to be due to the inhibition of angiogenesis elicited
by inﬂammatory mediators such as bradykinin and others formed
during the development of the tumor. In support of this hypothesis,
bradykinin B1 antagonists were previously shown to have antian-
giogenic activities [21]. The inhibitory effect of R-954 on the tumor
growth could also be due to its inhibitory effect on the vascular per-
meability and protein leakage as demonstrated previously by our
group [27].
Experimental evidence conﬁrms the presence of bradykinin B1
and B2 receptors in cancer tissues. Cervical cancer tissue displayed
higher expression of both B1 and B2 receptors than did normal
cervical tissue and the levels normalized following brachytherapy
[37]. Prostate cancer tissuewas found to express increased levels of
B1 receptors compared with normal prostate tissue [52]. Based on
these ﬁndings several B1 antagonists have been proposed for the
treatment of various cancers, particularly lung andprostate cancers
[48]. The BK antagonist CU-201was shown to induce apoptosis and
growth inhibition in various lung cancer and cancer cell lines [8,9].
It was found to be a very potent stimulus for apoptosis in cultured
SCLC, and it inhibited tumor growth of SCLC in athymic nude mice
[9]. Other antagonists were also shown to inhibit the growth of
prostate cancer in nude mice [49]. The Stewart group have devel-
oped a series of B1 antagonists and the lead compound, BKM-570,
was a very potent inhibitor of tumor growth in several types of
cancers in nude mouse xenografts. This impressive activity in vivo
is likely related to its potent inhibition of angiogenesis and matrix
metalloproteases as well as to stimulation of apoptosis in addi-
tion to its direct inhibition of cell growth. The numerous activities
in these compounds could provide a highly effective combination
therapy and have potential for drug development [51].
Our results also showed that the development of the tumor
in mice was associated with a large increase (up to 12-fold) of
blood cells, ascitic lavage cells and bone marrow cells. These effects
were reduced by 60–77% following treatment of the mice with vin-
cristine. R-954 produced a similar reduction of total cell numbers
in bone marrow, blood, and ascitic ﬂuid of EAT inoculated mice.
The observation that Ehrlich tumor is able to grow in almost all
mice strains suggests that the recognition and immune responses
to this tumor are independent of MHC [10]. It is an indication that
the control of Ehrlich tumor growth is rather related to innate
immunity, specially the inﬂammatory response. Our results are in
agreement with those of Bergamini-Santos et al. [5] who demon-
strated the importance of neutrophilic inﬂammatory response in
Ehrlich tumor growth progression. It appeared that the initial inhi-
bition caused by R-954 at the beginning of tumor progression
reduced the neutrophil inﬂux, thereby inhibiting the migration of
other cell types.
Our results also showed that the peritoneal ﬂuid of the mice
which were inoculated with EAT cells showed a large increase
of total protein, NO, PGE2 and TNF contents. The bradykinin B1
receptor antagonist reduced protein, NO, PGE2, and TNF levels in
the peritoneal ﬂuid of EAT inoculated mice by 56–86%. Vincristine
produced a similar but larger inhibitory effect on the content
of proteins, NO, PGE2 and TNF in the mouse peritoneal ﬂuid.
The leukocyte activation and migration induced by Ehrlich tumor
cell inoculation, and cell activation are elements of host defense
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hip between macrophage spreading and Ehrlich tumor growth
as alreadydescribed [38,39]. Similarly, the production of nitrogen
ntermediates such as NO has already been linked to the cytotoxic
apabilities of host macrophages (among others) against tumor
ells [24,25]. Macrophage NO production, in this respect, is known
o involve the cytokine network [25]. Bradykinin was shown to
ave inﬂammatory effects such as the activation of nuclear factor
appa B and the release of inﬂammatory cytokines (interleukin-1,
NF), chemokines, and prostaglandins [13,40,53] by acting on the
nducible bradykinin B1 receptor. The fact that the bradykinin B1
eceptor gene is regulated by a promoter region with binding sites
or transcription factors such as activator protein-1 andnuclear fac-
or kappaB,which are bothup-regulatedduring inﬂammation [29],
nd that interleukin-1, TNF and activation of mitogen-activated
rotein kinase are involved in the up-regulation of the bradykinin
1 receptor [31] can explain the present results.
The results of the ﬁnal set of experiments showed that the inoc-
lation of EAT cells in the rat paw produced a solid tumor which
eaked in size 6 days following the inoculation. In the subsequent
ays, there was a necrotizing tissue formation at the site of the
umor. The treatment with R-954 as well as with vincristine sig-
iﬁcantly reduced the paw edema and completely prevented the
ecrosis during the 15 days of the experimental protocol. These
esults clearly showed that the inhibition of bradykinin B1 receptor
ould block one of the mechanisms responsible for tumor growth
n this rat model almost as well as vincristine, a potent well known
ntineoplasic agent which blocks cell replication.
The exact signaling pathways involved in B1 receptor-mediated
umor growth are not fully known. The binding of an agonist to B1
eceptors on target cells activates the heterotrimeric Gq proteins.
t has been demonstrated that BK-induced activation of Gq sub-
nits promotes the growth of tumor cells via phosphorylation of
GFR and ERK [3]. Other groups have reported that B1 receptors
ctivated the mitogenic ERK pathway and induced prostate cancer
ell growth. The exact signal transduction pathway(s) used in the
ctivation of ERK in tumor cells remains unclear. The antagonismof
1 receptors was shown to attenuate prostate cancer cell growth
nd may be considered as an effective option for prostate cancer
reatment.
Based on experimental evidence from ours and other laborato-
ies, various hypotheses could be presented. First, B1 receptorsmay
egulate cell migration via activation of heterotrimeric G proteins
18,34]. Meigs et al. [34] reported that activated G proteins inhibit
adherin functions such as cell adhesion and that the expression of
onstitutively active G proteins promoted breast cancer cell migra-
ion in a wound healing assay. Second, B1 receptors can induce cell
igration via-arrestin proteinswhich are recruited to the plasma
embrane to participate in many G protein-coupled receptor-
egulated signal transduction events [41]. Finally, B1 receptors
ould regulate cancer cell movement via activation of matrix met-
lloproteinases, which promote degradation of the extracellular
atrix, an early event in cell migration and metastasis [12,26].
In summary, our results showed that a novel selective antag-
nist of the bradykinin B1 receptor, R-954 strongly inhibited
hrlich tumor growth and increased survival in rats and mice. The
nhibitory effects were compared with that of vincristine and the
echanismof action is discussed. Since local tumor control charac-
erized by total tumor regression (complete response) and growth
elay (partial response) coupled with normal tissue toxicity (sys-
emic toxicity) determine therapeutic efﬁcacy of any treatment
egimen, all therapeutic strategies need to be evaluated from both
spects. Many of the chemotherapeutic strategies using single or
combination of anticancer agents could show good local tumor
ontrol but the therapeutic efﬁcacy is often compromised by tissue
oxicity which reduced the cure i.e. the disease (tumor) free sur-
ival. The excellent antitumor efﬁcacy and absence of toxicity of
[
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R-954 suggest that it might be the prototype of a novel antitumor
drug.
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